Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
CohBar Inc is a biotechnology business based in the US. CohBar shares (CWBR) are listed on the NASDAQ and all prices are listed in US Dollars. CohBar employs 9 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.21 |
|---|---|
| 52-week range | $0.17 - $2.27 |
| 50-day moving average | $0.21 |
| 200-day moving average | $0.44 |
| Wall St. target price | $3.17 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.20 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.2051 from 2022-07-01
| 1 week (2022-06-24) | 16.53% |
|---|---|
| 1 month (2022-06-02) | 2.55% |
| 3 months (2022-04-01) | -37.85% |
| 6 months (2021-12-31) | -41.38% |
| 1 year (2021-07-02) | -84.58% |
|---|---|
| 2 years (2020-07-02) | -86.33% |
| 3 years (2019-07-02) | 1.75 |
| 5 years (2017-06-30) | 1.65 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -42.74% |
| Return on equity TTM | -75.77% |
| Profit margin | 0% |
| Book value | $0.26 |
| Market capitalisation | $16.5 million |
TTM: trailing 12 months
We're not expecting CohBar to pay a dividend over the next 12 months.
Over the last 12 months, CohBar's shares have ranged in value from as little as $0.17 up to $2.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CohBar's is 2.5227. This would suggest that CohBar's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CohBar, Inc. , a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.